rts logo

Arcutis Biotherapeutics Inc (ARQT) Stock Could Soon Reward Patient Investors

Arcutis Biotherapeutics Inc (NASDAQ: ARQT) is 176.78% higher on its value in year-to-date trading and has touched a low of $1.76 and a high of $15.21 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The ARQT stock was last observed hovering at around $9.10 in the last trading session, with the day’s loss setting it -0.16%.

Currently trading at $8.94, the stock is -13.57% and -9.90% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.23 million and changing -1.76% at the moment leaves the stock 37.18% off its SMA200. ARQT registered -33.53% loss for a year compared to 6-month gain of 195.05%.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

The stock witnessed a -12.18% loss in the last 1 month and extending the period to 3 months gives it a 152.54%, and is -11.40% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.88% over the week and 8.57% over the month.

Distance from 52-week low is 407.95% and -41.22% from its 52-week high.

The EPS is expected to grow by 37.10% this year.

Arcutis Biotherapeutics Inc (ARQT) Top Institutional Holders

The shares outstanding are 114.97M, and float is at 97.27M with Short Float at 19.80%.

Arcutis Biotherapeutics Inc (ARQT) Insider Activity

The most recent transaction is an insider purchase by Heron Patrick J,the company’sDirector. SEC filings show that Heron Patrick J bought 21,052 shares of the company’s common stock on Mar 04 ’24 at a price of $9.50 per share for a total of $0.2 million. Following the purchase, the insider now owns 8.79 million shares.

Arcutis Biotherapeutics Inc disclosed in a document filed with the SEC on Mar 04 ’24 that Watanabe Todd Franklinsold a total of 14,903 shares of the company’s common stock. The trade occurred on Mar 04 ’24 and was made at $11.12 per share for $0.17 million. Following the transaction, the insider now directly holds 0.87 million shares of the ARQT stock.

Still, SEC filings show that on Mar 04 ’24, Burnett Patrick () disposed off 4,782 shares at an average price of $11.12 for $53182.0. The insider now directly holds 269,300 shares of Arcutis Biotherapeutics Inc (ARQT).

Related Posts